Order Summary

In order to access content on the FENIX Marketplace, you must have an account.

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

By selecting this, I agree to receive emails from fenix.group.

You will be granted access to your FENIX Library to view the full article after sign up.
RETURN TO HOME
$0
Basal Insulin, Bolus Insulin, DPP-IVi, Dual/triple agonist, GLP-1RA, Glucagon, Glucose Monitoring, Insulin Delivery, SGLT2i

REWIND Filed; Empa T1DM, Nasal Glucagon Delayed; Lilly Q1 '19 Earnings Update

Here is a brief preview of this blast: Lilly hosted its Q1 '19 earnings call and provided updates to its diabetes business. Of note, Lilly disclosed that it submitted REWIND (US and EU), URLi (EU, Japan, and maybe the US), a connected prefilled pen (US), and the empa+lina+metXR triple combination (US). Furthermore, Lilly also disclosed two regulatory delays. FDA refused to accept the sNDA for Jardiance in T1DM for "technical reasons," and the review for Lilly’s nasal glucagon rescue product was extended by 3 months after FDA requested additional data. Below, FENIX provides thoughts and context to the significant Q1 '19 regulatory events in diabetes.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.